Clinical trials
Recurrent Ovarian Carcinoma clinical trials
Below are recruiting recurrent ovarian carcinoma clinical trials, each written for real people, not researchers. We’re tracking 105 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06964009RecruitingPhase 1
DT2216 plus paclitaxel for platinum-resistant ovarian cancer
This trial tests a new targeted therapy called DT2216 combined with the chemotherapy paclitaxel for people with ovarian cancer that is resistant to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT07144826RecruitingEarly Phase 1
Probiotic for Gut and Vaginal Health in Ovarian Cancer Chemotherapy
This trial tests whether taking a probiotic supplement can help balance the bacteria in your gut and vagina while you undergo chemotherapy for advanced ovarian cancer. It aims to see if this could improve your treatment experience or outcomes.
Columbus, OhioAges 18 years+ - NCT07340164RecruitingPhase 2
Trastuzumab deruxtecan vs standard care for recurrent ovarian cancer
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
Seoul, SeoulAges 18 years+ - NCT07480954RecruitingPhase 1/Phase 2
CAR-NK cell therapy for recurrent ovarian cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins often found on ovarian cancer cells. It is for people whose cancer has come back after at least two prior treatments.
Shenzhen, GuangdongAges 18–75 - NCT07617753RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Recurrent Ovarian Cancer
This trial tests a new type of cell therapy using modified natural killer cells (CAR-NK cells) that are trained to attack ovarian cancer cells. It's designed for patients whose cancer has come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT05610735RecruitingPhase 1/Phase 2
Study drug combination for ovarian cancer after platinum stops working
This Phase 1/2 trial tests a combination treatment for recurrent ovarian, fallopian tube, or primary peritoneal cancer when platinum chemotherapy stops working. If you qualify, the study aims to control the cancer and see how well the treatment is tolerated.
Louisville, KentuckyAges 18 years+ - NCT06560112RecruitingPhase 2
Combination therapy trial for recurrent ovarian cancer
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
ShanghaiAges 18 years+ - NCT05942300RecruitingPhase 1
CPI-0209 plus platinum chemo for recurring ovarian cancer
This Phase 1 trial tests CPI-0209 combined with the standard platinum chemotherapy approach in people whose ovarian (or related) cancer has returned after prior platinum treatment. The goal is to find a safe dose and see whether this combination can help keep the cancer under control.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06014528RecruitingPhase 2
IN10018 plus liposomal doxorubicin for platinum-resistant ovarian cancer
This trial tests if adding the drug IN10018 to standard chemotherapy (liposomal doxorubicin) can help women with ovarian cancer that has stopped responding to platinum-based treatments. It aims to see if the combination works better than chemotherapy alone.
BeijingAges 18 years+ - NCT03983226RecruitingPhase 2
Surgery plus niraparib for returning ovarian cancer
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05444270Recruiting
Radiation and medicine for recurrent ovarian cancer
This trial studies a “salvage” (next-line) cancer treatment for recurrent epithelial ovarian cancer, with or without a focused type of radiation. It may help by shrinking or controlling limited spots of cancer that have come back after prior standard treatment.
SeoulAges 19 years+ - NCT06799065RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.
Sarasota, FloridaAges 18 years+ - NCT06639074RecruitingPhase 2
Folate receptor dendritic cell vaccine for ovarian cancer
This trial tests a personalized vaccine made from your own immune cells, designed to target a protein called folate receptor alpha found on many ovarian cancer cells. It is for people who have finished initial chemotherapy and have no signs of cancer remaining, to try to prevent it from coming back.
Scottsdale, ArizonaAges 18 years+ - NCT07286240RecruitingPhase 2
QL1706 with chemo and anlotinib for recurrent ovarian cancer
This trial tests a combination of a new immunotherapy drug (QL1706), chemotherapy, and a targeted therapy (anlotinib) for ovarian cancer that has come back after standard platinum treatment. The goal is to see if this triple therapy can shrink tumors or slow the cancer's return.
Guangzhou, GuangdongAges 18–70 - NCT07741968Recruiting
Online program to ease fear of cancer returning
This study tests an online program designed to help women with advanced or certain types of breast or gynecologic cancer manage their fear of the disease progressing or returning. The program aims to reduce anxiety and improve quality of life.
Arcadia, CaliforniaAges 18 years+ - NCT07002346RecruitingPhase 3
Immunotherapy and bevacizumab for advanced ovarian clear cell cancer
This trial tests a combination of an immunotherapy drug (QL1706) and a targeted therapy (bevacizumab) for women with newly diagnosed advanced ovarian clear cell carcinoma. The goal is to see if this combination works better than standard treatment after surgery.
Wuhan, HubeiAges 18–75 - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT06543537Recruiting
A trial to help patients with advanced ovarian cancer plan their visits
This study tests a program to help patients and their doctors work together to set a plan for each visit. If you have advanced ovarian cancer and are getting chemotherapy at Dana-Farber, you may be able to join.
Boston, MassachusettsAges 18 years+ - NCT06660511RecruitingEarly Phase 1
Combination therapy for HER2-positive platinum-resistant ovarian cancer
This trial tests a combination of two drugs—Disitamab Vedotin and Anlotinib—for patients with ovarian cancer that has come back after platinum chemotherapy. It is designed for people whose tumors show a specific protein called HER2, and it aims to see if the combination is safe and effective.
Changsha, HunanAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Birmingham, AlabamaAges 18 years+ - NCT04878094RecruitingPhase 3
Test dye imaging during surgery for ovarian cancer
This study tests whether using a special imaging dye during surgery can help surgeons better manage parts of the bowel during operations for ovarian cancer. It may help guide whether a low anterior rectosigmoid resection and reconnection (anastomosis) are needed.
Basking Ridge, New JerseyAges Any age - NCT04361370Enrolling by invitationPhase 2
Olaparib plus pembrolizumab and bevacizumab after ovarian cancer
This trial tests whether adding olaparib, pembrolizumab, and bevacizumab as ongoing (“maintenance”) treatment can help control platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer that has responded to prior chemotherapy. It focuses on people whose tumors do NOT have BRCA1/2 gene mutations.
SeoulAges 20 years+ - NCT07495384Recruiting
CapsuleX and cisplatin for platinum-resistant ovarian cancer
This study tests a new treatment combination (CapsuleX plus cisplatin) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help when the cancer has progressed within 6 months of last platinum treatment.
Changchun, JilinAges 18 years+ - NCT05773859RecruitingPhase 1/Phase 2
Vaccination before surgery to treat advanced ovarian cancer
This trial studies a vaccine made from your immune cells (dendritic cell vaccine) given before chemotherapy and surgery. It aims to help your body recognize and fight ovarian cancer more effectively in people whose cancer is advanced and spread.
Nijmegen, GelderlandAges 18 years+
Hear when a new Recurrent Ovarian Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent ovarian carcinoma?
- Yes. Clin2 currently lists 105 recruiting recurrent ovarian carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent ovarian carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent ovarian carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.